CAR T-cell therapies, including Novartis’s Kymriah, Gilead / Kite’s Yescarta and Tecartus, and Celgene / Bristol Myers Squibb’s Breyanzi, have given new hope to patients with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL). Additionally, the March 2021 FDA approval of Bluebird Bio / Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) provides the first CAR T-cell therapy for R/R multiple myeloma; FDA approval is also expected for Janssen’s ciltacabtagene autoleucel (cilta-cel) in this indication. We explore how payers approach reimbursement of these expensive new therapies for NHL and multiple myeloma and how reimbursement decisions impact prescribing among surveyed hematologist-oncologists.
Questions Answered
What role do CAR T-cell therapies play in the treatment of NHL and multiple myeloma?
What are hematologist-oncologists' experiences with the use of Kymriah, Yescarta, and other CAR T-cell therapies so far?
What strategies will payers use to control utilization and costs of CAR T-cell therapies as more come to market?
What are hematologist-oncologists’ views on select emerging CAR T-cell therapies and other targeted agents in the late-phase pipeline?
Content Highlights
Geography: United States.
Primary research: Survey of 100 U.S. hematologist-oncologists; survey of 40 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs).
Fingertip Formulary: National formulary coverage and restrictions data for CAR T-cell therapies by commercial plans covering 161.9 million lives and more than 16 million Medicare Advantage lives.
Opportunities and challenges for emerging therapies.
Disease-specific special topic.
Product Description
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Non-Hodgkins Lymphoma and Multiple Myeloma / U.S. Access & Reimbursement / November 2021
Chris Lewis
Chris Lewis is a primary research manager at Clarivate. She is responsible for the coordination, content review, and content generation of U.S. Access & Reimbursement reports, including authoring select A&R reports on managed care trends. Before this position, Ms. Lewis was a senior analyst at HealthLeaders-InterStudy. She analyzed the managed care markets in California, New York, and Pennsylvania. She also launched and authored the Pharmacy Benefit Manager profile series. She received her bachelor’s degree from California State University in Sacramento.
Sorcha Cassidy, M.Res., Ph.D.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.
